Pfizer Inc. is a renowned global biopharmaceutical company that was established 170 years ago and is currently headquartered in New York. The company operates in over 125 countries and is a powerhouse in the research, development, manufacturing, and marketing of medicines and vaccines across various therapeutic areas, including oncology, immunology, internal medicine, rare diseases, and preventive vaccines.
With a market capitalization of approximately $146 billion, Pfizer falls into the “large-cap” category of companies worth $10 billion or more. Despite facing a decline in COVID-19 product demand post-pandemic, Pfizer continues to forge ahead with a robust lineup of innovative medicines and vaccines. The company’s expanding pipeline reflects its commitment to delivering breakthrough treatments and making a significant impact on global healthcare.
However, Pfizer’s stock performance has been lackluster in recent months. Over the past three months, PFE stock has seen a modest increase of 3.2%, slightly trailing behind the broader Dow Jones Industrial Average’s 4.4% return during the same period. Additionally, the stock has dropped by 7.2% from its 52-week high of $27.69 in October.
Looking at the longer-term performance, Pfizer’s shares have remained relatively flat over the past 12 months and have declined by 3.1% in 2025. In contrast, the Dow Jones Industrial Average has surged ahead, registering a 5.7% gain over the past year and an impressive 11.5% increase in 2025.
Despite these challenges, Pfizer’s shares have been trading above their 50-day and 200-day moving averages since the beginning of the month, signaling a potential shift in momentum in the company’s favor. The recent approval of Pfizer’s PADCEV plus Keytruda combination for the treatment of certain bladder cancer patients has also provided a glimmer of hope for the company.
While Pfizer has underperformed compared to its rival Amgen Inc., Wall Street analysts remain optimistic about the company’s prospects. The consensus rating from 23 analysts is a “Moderate Buy”, with an average price target of $28.43, suggesting a potential upside of around 10.6% from current levels.
In conclusion, despite facing challenges in the form of patent expirations and declining COVID-19 product sales, Pfizer remains focused on driving innovation and delivering impactful healthcare solutions. Investors may want to keep an eye on the company’s evolving pipeline and strategic initiatives to gauge its future performance.
